Caption Health, a Brisbane, Calif.-based medical artificial intelligence (AI) company, closed its $53m Series B funding round.
The round was led by existing investor DCVC. New investors Atlantic Bridge and cardiovascular medical device leader Edwards Lifesciences also participated, along with existing investor Khosla Ventures.
The company intends to use the funds to scale up its commercial operations, continue to develop its AI technology platform and form new partnerships to expand the use of Caption AI in additional care settings.
Led by Charles Cadieu, CEO, Caption Health provides Caption AI, an AI-guided medical imaging acquisition system, which allows healthcare providers to perform ultrasound and obtain diagnostic-quality images, to support clinical decision-making and deliver savings for medical institutions.
The Caption AI platform, which includes Caption Guidance™ and Caption Interpretation™, makes it radically easier to perform ultrasound and obtain diagnostic-quality images by providing:
- Expert Guidance – Caption Guidance provides 90-plus types of real-time feedback and instructions to emulate the guidance of an expert sonographer;
- Automated Quality Assessment – Caption Guidance helps standardize diagnostic-quality exams by accurately assessing, automatically recording, and seamlessly providing real-time feedback on diagnostic image quality;
- Intelligent Interpretation – Caption Interpretation produces an automated ejection fraction calculation—the most widely used measurement to assess cardiac function—from single or multiple cardiac ultrasound views commonly acquired at the point of care (AP4, AP2, PLAX).
Caption AI software is currently available fully integrated with a Terason uSmart 3200T Plus portable ultrasound system, which offers a full range of clinical applications including lung, vascular, and abdominal scanning.